Bill authorizes the National Institutes of Health (NIH) to support the creation of up to 20 pediatric research consortia focused on diseases such as Spinal Muscular Atrophy.
Friday, November 15, 2013 – 10:00am Health Subcommittee – 2322 Rayburn House Office Building, Washington DC
Many members of Congress brought up concerns about how FDASIA implementation is affecting Rare Disease Drug Development. Dr. Woodcock, FDA’s Director of the Center for Drug Evaluation & Research (CDER) explained how the rare diseases programs at the FDA have been hindered due to Sequestration.
The FDA Safety over Sequestration Act is bipartisan legislation that would exempt FDA user fees from sequestration. The bill amends the Budget Control Act. To sign onto the letter to support FDA SOS, contact Jenny Carey Carey@chi.org by Friday Dec. 6th.
Recent update: At the Energy & Commerce Congressional Hearing on FDASIA, Dr. Janet Woodcock, FDA’s Director of the Center for Drug Evaluation & Research (CDER) explained how the rare diseases programs at the FDA have been hindered due to Sequestration. The EveryLife Foundation is encouraging all rare disease patient organizations to support FDA-SOS.
Join the EveryLife Foundation for Rare Diseases for a conference call and webinar on the implementation of the ULTRA/FAST Legislation that was included in FDASIA to empower the FDA to give rare disease treatments access to the Accelerated Approval pathway. The FDA recently issued a draft guidance on the Expedited Approval Programs which they say fulfills the FDASIA mandate, however the guidance does not address issues specific for rare diseases as required by FDASIA. Please join the webinar to learn about the URGENT ACTION that is needed from the patient community to ensure rare diseases have access to the Accelerated Approval pathway.
One of the key provisions from the Orphan Drug Act is at risk of begin eliminated! The Orphan Drug Tax Credit (ODTC) is part of a package of incentives enacted in 1983 in the Orphan Drug Act that encourage drug companies to develop products for rare diseases.
The Senate’s plan is to start at zero, eliminating all tax credits, meaning the rare disease community must fight to get ODTC put back in the bill. In the House, everything is on the table for elimination, including ODTC.
Drug companies need more incentives to develop rare disease treatments, not less. Congress must hear from the patient community that the Orphan Drug Tax Credit is important to them. To add your organization to letter to protect the Orphan Drug Act, please contact Lauren Neff: email@example.com. Deadline to sign on is COB, July 24th.
House Majority Leader Eric Cantor is calling for medical research to gain precedence over some other issues, as Congress tries to balance competing priorities with limited dollars.
Cantor said his interest in medical research partly comes from watching his father suffer for more than a decade from a rare neurological disorder known as multiple system atrophy or Shy-Drager syndrome.
By Melissa Attias, Roll Call Staff June 3, 2013, 3:51 p.m.
CQ NEWS – June 7, 2013 – 3:24 p.m. By Daniel Newhauser, CQ Roll Call
House Majority Leader Eric Cantor and his staff are working behind the scenes to avoid another embarrassment this month when they bring to the floor a bill that would increase funding for pediatric research.
The measure is part of the Virginia Republican’s agenda to soften the Republican image. But it is running up against the same hardline conservatives who forced leaders in April to pull from the House floor a bill (HR 1549) that would have reprioritized funding within President Barack Obama’s health care law (PL 111-148,PL 111-152).
To sign on to support this legislation, email Melissa at firstname.lastname@example.org
The Newborn Screening Save Lives Reauthorization Act (H.R. 1281) reauthorizes critical federal programs that provide assistance to states to improve and expand their newborn screening programs; support parent and provider education; and ensure laboratory quality and surveillance for newborn screening.
Congressman Morgan Griffith (R-VA), Congressman Scott Peters (D-CA), and Congressman Michael McCaul (R-TX) today introduced H.R. 2090, the Patient Choice Act of 2013, which aims to speed up the Food and Drug Administration’s (FDA) approval of drugs for patients. The Patient Choice Act would create a provisional approval process for innovative drugs and treatments while giving patients with terminal diseases the option to purchase these new therapies at their own expense.